![Luc Marengère](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Luc Marengère
Directeur/Membre du Conseil chez
Ixchelsis Ltd.
Profil
Luc Marengère currently works at Emovi, Inc., as Director, Ixchelsis Ltd., as Director, Modulate Therapeutics, Inc., as Director, AurKa Pharma, Inc., as Director, Access Vascular, Inc., as Director, Panthera Dental Inc., as Director, TVM Life Science Management, Inc., as Managing Partner from 2012, and TVM Capital GmbH, as Managing Partner from 2012.
Dr. Marengère also formerly worked at Cita NeuroPharmaceuticals, Inc., as Director, Cytochroma, Inc., as Director, CoLucid Pharmaceuticals, Inc., as Independent Director from 2015 to 2017, Rapid Micro Biosystems, Inc., as Director, Acer Therapeutics, Inc., as Director, Argos Therapeutics, Inc., as Director, Aegera Therapeutics, Inc., as Director, Trillium Therapeutics, Inc., as Director, LymphoSign, Inc., as Director, VisualSonics, Inc., as Director, Opexa Therapeutics, Inc., as Director, Albireo AB, as Director, PRCL Research Inc., as Director, Acer Therapeutics, Inc., as Independent Director from 2017 to 2019, Amgen, Inc., as Researcher, Lumira Capital Investment Management, Inc., as Investment Manager, VenGrowth Capital Partners, Inc., as Managing General Partner, CDP Capital Private Equity, as Co-President & Partner, MedTech Partners, Inc., as Analyst, University Medical Discoveries, Inc., as Principal, and VG Partners, as Managing General Partner.
Dr. Marengère received his graduate degree from Queen's University, undergraduate degree from the University of Ottawa, and doctorate degree from the University of Toronto.
Postes actifs de Luc Marengère
| Sociétés | Poste | Début |
|---|---|---|
Ixchelsis Ltd.
 Ixchelsis Ltd. BiotechnologyHealth Technology Develops oxytocin receptor antagonist for the treatment of premature ejaculation | Directeur/Membre du Conseil | - |
TVM Life Science Management, Inc.
 TVM Life Science Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Corporate Officer/Principal | 01/03/2012 |
Panthera Dental Inc.
 Panthera Dental Inc. Medical SpecialtiesHealth Technology Manufactures and markets CAD/CAM prosthetic implant solutions and dental sleep appliances | Directeur/Membre du Conseil | - |
Emovi, Inc.
 Emovi, Inc. Medical/Nursing ServicesHealth Services Offers orthopedic services | Directeur/Membre du Conseil | - |
Access Vascular, Inc.
 Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Directeur/Membre du Conseil | - |
TVM Capital GmbH
 TVM Capital GmbH Investment ManagersFinance TVM Capital invests in companies located in the United States and Europe. The firm focuses on information technology, communications and life sciences sectors. It provides financing for early and later stage capital requirements. It also acts as lead or co-lead investor. | Private Equity Investor | 01/03/2012 |
Anciens postes connus de Luc Marengère
| Sociétés | Poste | Fin |
|---|---|---|
| ACER THERAPEUTICS INC. | Directeur/Membre du Conseil | 17/05/2019 |
| COLUCID PHARMACEUTICALS INC | Directeur/Membre du Conseil | 01/03/2017 |
Cytochroma, Inc.
 Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Directeur/Membre du Conseil | 16/06/2011 |
| ░░░ ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | - |
Formation de Luc Marengère
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
49
Relations au 1er degré
32
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 32 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Cita NeuroPharmaceuticals, Inc.
 Cita NeuroPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small molecule drugs | Health Technology |
Cytochroma, Inc.
Cytochroma, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets prescription products for the prevention of vitamin D insufficiency | Health Technology |
CoLucid Pharmaceuticals, Inc.
 CoLucid Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for neurological disorders | Health Technology |
Rapid Micro Biosystems, Inc.
 Rapid Micro Biosystems, Inc. Industrial MachineryProducer Manufacturing Develops automation solutions for pharmaceutical and healthcare manufacturing products | Producer Manufacturing |
Acer Therapeutics, Inc. /Old/
 Acer Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Develops therapeutics for the treatment of orphan diseases. | Health Technology |
Lumira Capital Investment Management, Inc.
 Lumira Capital Investment Management, Inc. Investment ManagersFinance LUMIRA invests in revenue stage companies that are both privately held and publically traded companies located in the Canada and the United States. The firm focuses on sectors of therapeutic products and medical devices. It participates in the early stage capital financing. | Finance |
TVM Capital GmbH
TVM Capital GmbH Investment ManagersFinance TVM Capital invests in companies located in the United States and Europe. The firm focuses on information technology, communications and life sciences sectors. It provides financing for early and later stage capital requirements. It also acts as lead or co-lead investor. | Finance |
VenGrowth Capital Partners, Inc.
 VenGrowth Capital Partners, Inc. Investment ManagersFinance The VenGrowth Funds invest in small and mid-sized private Canadian companies in the technology, life sciences and tradition industries sectors. The Criterion Global Dividend Fund invests in blue-chip multinational companies selected by Merrill Lynch International. The Fund is also available unhedged. The Criterion International Equity Fund is actively sub-advised by The Boston Company. The Fund invests in international stocks outside of North America, with a GARP strategy. It is also available unhedged. The Criterion Water Infrastructure Fund invests globally in companies related to water delivery. The Fund is also available unhedged. The Criterion Global Clean Energy Fund invests in companies involved in the global transition to cleaner energies and lower carbon emissions. The Fund is also available unhedged. The Criterion Diversified Commodities Currency Hedged Fund allows Canadian investors to participate directly in the diversified commodities index UBS Bloomberg CMCI AM. The Criterion US Buyback Fund invests in US companies with the best record of net share buybacks. It is also available unhedged. | Finance |
Argos Therapeutics, Inc.
 Argos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes personalized immunotherapies for the treatment of cancer and infectious diseases | Health Technology |
CDP Capital Private Equity
 CDP Capital Private Equity Investment ManagersFinance CDPQ invests in ESG companies located in the United States, Europe, Latin America, Canada and Asia-Pacific regions. The firm focuses on a broad range of sectors and industries. It provides financing for growth stage capital requirements with an investment size ranging from CAD 75 - 500 million. It acquires minority stake. | Finance |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Ottawa
 University of Ottawa Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aegera Therapeutics, Inc.
 Aegera Therapeutics, Inc. BiotechnologyHealth Technology Manufactures and develops drugs | Health Technology |
MedTech Partners, Inc.
 MedTech Partners, Inc. Investment ManagersFinance MTP generally invests in research and technologies at an early stage of development, even prior to a full evaluation of commercial potential. Selection criteria include the potential size of the market, the credibility and efforts of the principal investigators, the uniqueness of the discovery and the patentability of the discovery. Investments are made by MTP or cover costs relating to patenting, demonstration of proof-of-principle, prototype development and market analysis. | Finance |
Trillium Therapeutics, Inc. /Old/
 Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Provides research and development of pharmaceuticals | Commercial Services |
LymphoSign, Inc.
 LymphoSign, Inc. BiotechnologyHealth Technology Develops drugs for cancer treatment | Health Technology |
VisualSonics, Inc.
 VisualSonics, Inc. Medical SpecialtiesHealth Technology Develops vivo micro imaging systems | Health Technology |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops autologous personalized cell therapies for the treatment of various diseases. | Health Technology |
University Medical Discoveries, Inc.
 University Medical Discoveries, Inc. Investment ManagersFinance UMDI focuses on seed and early-stage investments in the medical and life sciences. They help develop and commercialize research done by entrepreneurs and scientists at Canadian universities, hospitals and research institutes. The CIHR, MDS, and MedTech Partners Inc have also joined forces to launch the University Medical Discoveries Fund (UMDF). The CMDF is considered a partner of the UMDF. The UMDF’s “focus is to help develop and commercialize early-stage biomedical innovations” at Canadian universities and since 1996 it has invested in 31 early stage companies. This relationship between the CIHR and CMDF goes further. | Finance |
Emovi, Inc.
Emovi, Inc. Medical/Nursing ServicesHealth Services Offers orthopedic services | Health Services |
Albireo AB
 Albireo AB Pharmaceuticals: MajorHealth Technology Develops bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders | Health Technology |
TVM Life Science Management, Inc.
TVM Life Science Management, Inc. Investment ManagersFinance Acts as an alternative investment manager | Finance |
Ixchelsis Ltd.
Ixchelsis Ltd. BiotechnologyHealth Technology Develops oxytocin receptor antagonist for the treatment of premature ejaculation | Health Technology |
PRCL Research Inc.
 PRCL Research Inc. Medical/Nursing ServicesHealth Services Develops and proofs a compound for the treatment of chronic inflammatory diseases | Health Services |
VG Partners
 VG Partners Investment ManagersFinance Private equity investment firm | Finance |
Modulate Therapeutics, Inc.
 Modulate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops medicine compound for re-engage the immune system | Health Technology |
AurKa Pharma, Inc.
 AurKa Pharma, Inc. BiotechnologyHealth Technology Develops medication for cancer treatment | Health Technology |
Access Vascular, Inc.
Access Vascular, Inc. Medical SpecialtiesHealth Technology Access Vascular, Inc. engages in the development and manufacture of medical devices. It provides hydrogel-based medical devices, such as catheter and stenst to improve venous access. The firm also improves peripherally inserted central catheter, hemodialysis, implantable ports, and drug delivery devices. The company was founded by James Biggins in 2015 and is headquartered in Bedford, MA. | Health Technology |
Acer Therapeutics, Inc.
 Acer Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops and commercializes therapies for serious rare and life-threatening diseases | Health Technology |
Panthera Dental Inc.
Panthera Dental Inc. Medical SpecialtiesHealth Technology Manufactures and markets CAD/CAM prosthetic implant solutions and dental sleep appliances | Health Technology |
Choisissez Zonebourse 
